Harlow S P, Rodriguez-Bigas M, Mang T, Petrelli N J
Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Ann Surg Oncol. 1995 May;2(3):228-32. doi: 10.1007/BF02307028.
Locally recurrent rectal cancer is a difficult management problem for the surgical oncologist. Current therapies including radical surgery, radiation and chemotherapy have had little success in producing curative results for these patients. This study incorporated intraoperative photodynamic therapy (PDT) as an adjunct to radical surgery for the treatment of locally recurrent rectal cancer.
Twenty-two patients were enrolled in a prospective feasibility study and injected with Photofrin (Quadra Logic Technologies, Vancouver, British Columbia, Canada) before surgery. Eight patients were found to be candidates and received PDT after surgical exploration and resection. Seven patients had rectal adenocarcinoma and one had squamous cell carcinoma of the anal canal.
Based on the indication for PDT, three patient groups were evaluated: group A, resection of all gross disease with negative pathologic margins in four patients; group B, resection of gross disease with positive pathologic margins in two; and group C, residual bulky tumor in two patients. There was one perioperative death (12.5%), not related to PDT, and one major morbidity due to PDT (12.5%). Local recurrence occurred in six patients (two in group A, two in group B, two in group C). Mean overall survival was 15.4 months for group A, 6.5 months for group B, and 24.5 months for group C.
The results of this study suggest that intraoperative PDT may be administered safely in patients undergoing resection of recurrent rectal cancer. However, its use in the present state of technology appears to be inadequate for control of disease, particularly if bulky tumor or residual microscopic disease is left behind.
局部复发性直肠癌对外科肿瘤学家来说是一个难以处理的问题。目前的治疗方法,包括根治性手术、放疗和化疗,在使这些患者获得治愈性结果方面收效甚微。本研究将术中光动力疗法(PDT)作为根治性手术的辅助手段,用于治疗局部复发性直肠癌。
22例患者纳入一项前瞻性可行性研究,术前注射了光敏剂(加拿大不列颠哥伦比亚省温哥华市Quadra Logic Technologies公司生产)。8例患者被确定为合适人选,在手术探查和切除后接受了PDT治疗。7例患有直肠腺癌,1例患有肛管鳞状细胞癌。
根据PDT的适应证,对三组患者进行了评估:A组,4例患者切除所有肉眼可见病变且病理切缘阴性;B组,2例患者切除肉眼可见病变但病理切缘阳性;C组,2例患者有残留的大块肿瘤。围手术期死亡1例(12.5%),与PDT无关,因PDT导致严重并发症1例(12.5%)。6例患者出现局部复发(A组2例,B组2例,C组2例)。A组患者的平均总生存期为15.4个月,B组为6.5个月,C组为24.5个月。
本研究结果表明,术中PDT可在复发性直肠癌切除患者中安全应用。然而,就目前的技术水平而言,其在控制疾病方面似乎并不充分,特别是当留下大块肿瘤或残留微小病变时。